Los Angeles Times | May 16, 2022
“This is a very good vaccine, but the FDA has slow-walked it every step of the way,” said Georgetown University’s Lawrence Gostin, an expert in public health law. Manufacturing hiccups raised early concerns among U.S. regulators. But those have long since been resolved, and Novavax has said it is on track to produce 2 billion doses this year.